Positive Data on Novartis Jakavi
Positive Data on Novartis Jakavi
Novartis (NVS – Snapshot Report) announced positive data from a phase III trial, RESPONSE, on blood cancer drug Jakavi. Novartis is seeking a label expansion for Jakavi for the indication of … We remind investors that Jakavi is already approved in …
Read more on Zacks.com
Healthcare Stocks Mixed in Afternoon Trade; Northwest Biometrics Jumps 13 …
The Paul Ehrlich Institute approved a "Hospital Exemption" early access program under Section 4b of German Drug Law, allowing the company to provide the experimental drug treat both Glioblastoma multiforme and lower grade gliomas outside clinical …
Read more on NASDAQ
Healthy Habits: Poison-proof your home
I honestly don't remember what advice she got or if there was any treatment, but what I do remember is how calm she was when she hung up. More than 3 million calls were made to America's 56 Poison Control Centers in 2012. You might think that these …
Read more on Utica Observer Dispatch
Related Drug Treatment News 2012 Information…